Our Clinical Programs at Alumis Inc.

Our Clinical Programs at Alumis Inc.

Alumis Inc. Presents at Stifel Virtual Immunology and Inflammation Forum.

Careers, Values and Life at Alumis Inc.

Careers, Values and Life at Alumis Inc.

Our Precision Approach to Science | Alumis Inc.

Clinical Trials | ESK-001 | Lonigutamab | Alumis Inc.

The leadership team and Board of Directors at Alumis Inc.

Our Precision Approach to Science | Alumis Inc.

The leadership team and Board of Directors at Alumis Inc.

The leadership team and Board of Directors at Alumis Inc.

Clinical Trials | ESK-001 | Lonigutamab | Alumis Inc.

The leadership team and Board of Directors at Alumis Inc.

Q&A: Alumis Inc. Initiates Phase 3 Clinical Program for ESK-001 in ...

The leadership team and Board of Directors at Alumis Inc.

The leadership team and Board of Directors at Alumis Inc.

The leadership team and Board of Directors at Alumis Inc.

The leadership team and Board of Directors at Alumis Inc.

The leadership team and Board of Directors at Alumis Inc.

Alanna Muldoon - Clinical Trial Manager at Alumis | The Org

The leadership team and Board of Directors at Alumis Inc.

Careers, Values and Life at Alumis Inc.

Clinical Trials | ESK-001 | Lonigutamab | Alumis Inc.

The leadership team and Board of Directors at Alumis Inc.

Careers, Values and Life at Alumis Inc.

A pipeline of oral therapies to address immune dysfunction | Alumis Inc.

Alumis Soars 30% on Insider Confidence and Clinical Catalysts: What’s ...

A pipeline of oral therapies to address immune dysfunction | Alumis Inc.

Alumis Announces Upsized $259M Series C Financing to Advance Clinical ...

Alumis Inc.

A pipeline of oral therapies to address immune dysfunction | Alumis Inc.

A pipeline of oral therapies to address immune dysfunction | Alumis Inc.

A pipeline of oral therapies to address immune dysfunction | Alumis Inc.

Alumis Inc.

Biotech Firm Acelyrin Inc. to Merge with Alumis Inc. in $320M Deal ...

Alumis to Present at Oppenheimer Conference: A Glimpse into the Future ...

Alumis at #ACTRIMSForum 2025: Poster presentations on A-005 for MS ...

Alumis Inc. Completes Merger with ACELYRIN, Boosts Balance Sheet and ...

Alumis on LinkedIn: This week, our President and CEO, Martin Babler and ...

Alumis begins patient dosing in OPTYK-1 Phase 2 clinical trial for the ...

Alumis Announces Initiation of Patient Dosing in Phase 2 Clinical Trial ...

Alumis to present 52-week data on ESK-001 in psoriasis at #AAD2025 ...

Phase 3 Trial Fully Enrolled for Alumis Oral Psoriasis Drug ESK-001 ...

Alumis on LinkedIn: #lupus #lupusresearch #lupusawarenessmonth

Investigational TYK2 Inhibitor from Alumis Performs Well in Phase 3 ...

Alumis on LinkedIn: #hiring #biotech

Alumis completes patient enrollment in LUMUS Phase 2b trial for ESK-001 ...

ALMS - Alumis | Fundamentei

Alumis Presents Data Highlighting ESK-001's Potential as a High ...

Alumis on LinkedIn: #tyk2 #cns

Skin Condition & Dermatology Clinical Trials Hamilton ON

Alumis (@_Alumis) / Posts / X

Wall Street Is Still Sleeping on This Breakthrough Biotech — Why Alumis ...

Alumis and ACELYRIN Join Forces to Drive Late-Stage Immunology ...

Alumis logo in transparent PNG and vectorized SVG formats

Alumis (@_Alumis) / Posts / X

Alumis and ACELYRIN Announce Strategic Merger

Alumis Stock Hits Record High As Wall Street Cheers Phase 3 Psoriasis ...

Alumis (ALMS) IPO deck

Alumis (@_Alumis) / Posts / X

#acr2024 | Alumis

Alumis (@_Alumis) / Posts / X

Alumis Signs a Definitive Merger Agreement with ACELYRIN to Develop ...

Alumis (@_Alumis) / Posts / X

Alumis (ALMS) Stock Rises Following Strategic Partnership

Alumis (@_Alumis) / Posts / X

Alumis Raises $250 Million in Downsized IPO, Private Placement - Bloomberg

Alumis readies $300 million IPO ahead of Phase 3 trial for plaque ...

Alumis on LinkedIn: #psoriasis #aad2024

#aad2025 | Alumis

Alumis | The Org

Alumis (@_Alumis) / Posts / X

Alumis Inc: Year-End 2025 Financial Results and Strategic TYK2 Pipeline ...

#immunology | Alumis

We are excited to welcome Sara Ramseyer Klein as our General Counsel ...

ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of ...

Alumis on LinkedIn: The Alumis team is skillfully built of scientists ...

ALUMIS | LinkedIn

Alumis (@_Alumis) / Posts / X

Alumis Inc (ALMS) Takes a Bold Step Forward with Its Initial Public ...

Alumis (ALMS) Merges with ACELYRIN

Alumis on LinkedIn: #aanhpi #aanhpiheritagemonth #aanhpimonth

ACELYRIN, Alumis Merger Approved

Alumis on LinkedIn: #opcolifesciences

Alumis Signs a Definitive Merger Agreement with ACELYRIN to Develop ...

WIB | Work in biotech

Alumis將參加全球醫療投資者大會分享新進展 - ss future

Thank You!

XBRL Viewer

Home | International Psoriasis Council

Dermatology Education Foundation

Alumis' Investigational Lead Candidate Supports Superior Profile Than ...

Piper Heartland Healthcare Capital | Piper Sandler

Alumis: $259 Million Raised To Develop Therapies For Immune-Mediated ...

Phase 2b Trial Completes Enrollment for Novel Oral Lupus Treatment ESK ...

Srushti Panchal on LinkedIn: #alumis #syneoshealth #clinicalresearch # ...

Corporate Members | International Psoriasis Council

ALMS Q3 2025 Earnings Report on 11/13/2025

Building teams and supporting Life Sciences careers | Meet Life Sciences

Oppenheimer names 'best of the best' smid-cap stocks – Oninvest

Inside the SLE Pipeline: Patient Enrollment Complete in Phase 2b Trial ...

EDGAR Filing Documents for 0001104659-26-001410